Clinical Pipeline Phase IIa trial in hypovolemia due to blood loss for VBI-1 and a Phase 3 program for VBI-S targeting septic shock, signaling ongoing clinical momentum and upcoming high-value manufacturing and regulatory milestones to align with potential partnerships or supply agreements.

Global Market Expansion Strategic push to Sub-Saharan Africa and other regions, with a dedicated regional strategy tied to Series B financing, presenting opportunities for regional distributors, clinical collaborations, and local commercialization partnerships.

Strategic Partnerships Recent collaboration with Propelevate and participation in major partnering events (BIO Partnering @ JPM Week) create entry points for co-development, licensing, and joint ventures with larger biopharma or specialty fluid resuscitation players.

Safety and Efficacy Advantage VBI-1 and VBI-S leverage phospholipid nanoparticle technology to address hypovolemia with potential reductions in adverse events and improved outcomes, offering a compelling value proposition for early adoption discussions with hospitals, trauma centers, and military/tactical medicine programs.

Funding and Scale Revenue expectations in the mid-range with modest funding needs suggest an opportunity to engage investors and strategic buyers focused on late-stage biotech assets, while preparing for scalable manufacturing and global clinical trial expansion.